A Phase 4 interventional study of 4% chlorhexidine gluconate soap-like solution and standard soap in Hospital Infection, sponsored by University Of Perugia. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by University Of Perugia · Phase 4, Interventional, and Prevention
The study will assess the utility of 4% chlorhexidine gluconate (CHG) daily bathing to reduce hospital acquired infections in patients admitted to intensive care units. One group will be daily bathed with 4% CHG and the other group with standard soap.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 449 is above the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →University Of Perugia is the lead sponsor of 51 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
Drug: 4% chlorhexidine gluconate soap-like solution
daily bathing with standard soap
Other: standard soap
1. humidify the whole body surface with the exception of the face using water-impregnated washcloths 2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG 3. wait for at least 30 seconds 4. rinse using water-impregnated washcloths
1. humidify the whole body surface with the exception of the face using water-impregnated washcloths 2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face 3. wait for at least 30 seconds 4. rinse using water-impregnated washcloths
hospital acquired infections incidence
cumulative incidence of bloodstream infections (BSI), central line-associates BSI (CLABSI), urinary tract infections (UTI), catheter-associated UTI (CAUTI) and ventilator-associated pneumonias (VAP)
Time frame: infections occured 48 hours after admission to ICU/PC-ICU
Ventilator-associated pnemonias (VAP) incidence
VAP incidence
Time frame: infections occured 48 hours after admission to ICU/PC-ICU
Bloodstream infections (BSI) incidence
BSI incidence
Time frame: infections occured 48 hours after admission to ICU/PC-ICU
central-line associated BSI (CLABSI) incidence
CLABSI incidence
Time frame: infections occured 48 hours after admission to ICU/PC-ICU
urinary tract infections (UTI) incidence
UTI incidence
Time frame: infections occured 48 hours after admission to ICU/PC-ICU
catheter associated UTI (CAUTI) incidence
CAUTI incidence
Time frame: infections occured 48 hours after admission to ICU/PC-ICU
4% CHG daily bathing safety
overall mortality in the treatment and control arm
Time frame: at discharge, approximately up to 10 days
4% CHG daily bathing-related adverse events
4% CHG daily bathing-related adverse events in the treatment arm compared to standard soap-related adverse events
Time frame: at discharge, approximately up to 10 days
time till infection
time between admission to ICU/PC-ICU and infection occurrence
Time frame: at discharge, approximately up to 10 days
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Of Perugia